Immix Biopharma (IMMX) Non-Current Assets (2020 - 2026)

Immix Biopharma has reported Non-Current Assets for 7 years, with the latest figure at $3.5 million in Q1 2026.

• Quarterly Non-Current Assets rose 13.76% year-over-year to $3.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.9 million (up 43.02% YoY) and the FY2025 annual result came in at $3.6 million, up 31.0% from the prior year.
• Non-Current Assets eased to $3.5 million in Q1 2026 per IMMX's latest filing, from $3.6 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $3.6 million in Q4 2025 and troughed at $4126.0 in Q3 2022.
• A 5-year average of $1.5 million and a median of $1.4 million in 2024 frame the typical range for Non-Current Assets.
• The sharpest annual moves came in 2023 and 2026: Non-Current Assets surged 3411.05% in 2023, then grew 13.76% in 2026.
• Over 5 years, Non-Current Assets stood at $10284.0 in 2022, then soared by 1236.15% to $137410.0 in 2023, then soared by 1901.34% to $2.8 million in 2024, then soared by 31.0% to $3.6 million in 2025, then declined by 1.7% to $3.5 million in 2026.
• According to Business Quant data, Non-Current Assets over the past three periods registered $3.5 million, $3.6 million, and $3.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.